Cortico-subcortical neuromodulation involved in the amelioration of prepulse inhibition deficits in dopamine transporter knockout mice

Neuropsychopharmacology

Volumn 37, Issue 11, 2012, Pages 2522-2530

  Arime, Yosefu ^a,b   Kasahara, Yoshiyuki ^a   Hall, F Scott ^c   Uhl, George R ^c   Sora, Ichiro ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

medial prefrontal cortex; mouse; neural circuits; norepinephrine reuptake inhibitor; prepulse inhibition

Indexed keywords

DOPAMINE TRANSPORTER; FLUOROGOLD; NISOXETINE; PROTEIN C FOS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASOLATERAL AMYGDALA; DRUG EFFECT; FEMALE; GENOTYPE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFORMATION PROCESSING; MALE; MEDIAL PREFRONTAL CORTEX; MOUSE; NEUROMODULATION; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SCHIZOPHRENIA; SUBICULUM; WILD TYPE;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG ADMINISTRATION ROUTES; FLUOXETINE; GENE EXPRESSION REGULATION; GLUTAMATE DECARBOXYLASE; GLUTAMINASE; INHIBITION (PSYCHOLOGY); MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEUROTRANSMITTER AGENTS; NEUROTRANSMITTER UPTAKE INHIBITORS; PROTO-ONCOGENE PROTEINS C-FOS; SEX FACTORS; STARTLE REACTION; STILBAMIDINES;

EID: 84866364150     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.114     Document Type: Article

References (46)

1. Arime Y, Yamashita M, Fukushima S, Shen H-W, Hagino Y, Hall FS et al (2006). Norepinephrine transporter blockade reversed the prepulse inhibition deficits in dopamine transporter knockout mice. The Society for Neuroscience 36th Annual Meeting, Atlanta, USA.
2. Bisler S, Schleicher A, Gass P, Stehle JH, Zilles K, Staiger JF (2002). Expression of c-Fos, ICER, Krox-24 and JunB in the whisker-tobarrel pathway of rats: time course of induction upon whisker stimulation by tactile exploration of an enriched environment. J Chem Neuroanat 23: 187-198. (Pubitemid 34171637)
3. Braff DL, Geyer MA, Swerdlow NR (2001). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156: 234-258. (Pubitemid 32705488)
4. Brog JS, Salyapongse A, Deutch AY, Zahm DS (1993). The patterns of afferent innervation of the core and shell in the 00accumbens00 part of the rat ventral striatum: immunohistochemical detection of retrogradely transported fluoro-gold. J Comp Neurol 338: 255-278. (Pubitemid 23339283)
5. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH et al (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27: 699-711. (Pubitemid 35335888)
6. Carboni E, Tanda GL, Frau R, Di Chiara G (1990). Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55: 1067-1070.
7. Carr DB, O0Donnell P, Card JP, Sesack SR (1999). Dopamine terminals in the rat prefrontal cortex synapse on pyramidal cells that project to the nucleus accumbens. J Neurosci 19: 11049-11060. (Pubitemid 30235748)
8. Deutch AY, Duman RS (1996). The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience 70: 377-389. (Pubitemid 126755251)
9. Ellenbroek BA, Budde S, Cools AR (1996). Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex. Neuroscience 75: 535-542. (Pubitemid 26361342)
10. Fendt M, Schwienbacher I, Koch M (2000). Amygdaloid N-methyl-D-aspartate and gamma-aminobutyric acid(A) receptors regulate sensorimotor gating in a dopamine-dependent way in rats. Neuroscience 98: 55-60. (Pubitemid 30349143)
11. Gehlert DR, Thompson LK, Hemrick-Luecke SK, Shaw J (2008). Monoaminergic compensation in the neuropeptide Y deficient mouse brain. Neuropeptides 42: 367-375.
12. Geyer MA (2006). Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? Dialogues Clin Neurosci 8: 9-16.
13. Geyer MA, Dulawa SC (2003). Assessment of murine startle reactivity, prepulse inhibition, and habituation. Curr Protoc Neurosci Chapter 8, Unit 8 17.
14. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC et al (2007). Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 64: 1115-1122. (Pubitemid 47529336)
15. Grace AA, Floresco SB, Goto Y, Lodge DJ (2007). Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 30: 220-227. (Pubitemid 46654234)
16. Hasue RH, Shammah-Lagnado SJ (2002). Origin of the dopaminergic innervation of the central extended amygdala and accumbens shell: a combined retrograde tracing and immunohistochemical study in the rat. J Comp Neurol 454: 15-33. (Pubitemid 35278452)
17. Ishii D, Matsuzawa D, Kanahara N, Matsuda S, Sutoh C, Ohtsuka H et al (2010). Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway. Neurosci Lett 471: 53-57.
18. Iversen SD, Iversen LL (2007). Dopamine: 50 years in perspective. Trends Neurosci 30: 188-193. (Pubitemid 46654233)
19. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-225. (Pubitemid 29067401)
20. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM et al (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64: 633-647. (Pubitemid 46878665)
21. Lewis DA, Lieberman JA (2000). Catching up on schizophrenia: natural history and neurobiology. Neuron 28: 325-334.
22. Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H (2010). Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 77: 317-326.
23. Margolis EB, Lock H, Chefer VI, Shippenberg TS, Hjelmstad GO, Fields HL (2006). Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci USA 103: 2938-2942.
24. Meredith GE (1999). The synaptic framework for chemical signaling in nucleus accumbens. Ann N Y Acad Sci 877: 140-156. (Pubitemid 29351856)
25. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT (2002). Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22: 389-395. (Pubitemid 34049076)
26. Mueser KT, McGurk SR (2004). Schizophrenia. Lancet 363: 2063-2072. (Pubitemid 38781110)
27. Ohashi K, Hamamura T, Lee Y, Fujiwara Y, Suzuki H, Kuroda S (2000). Clozapine-and olanzapine-induced Fos expression in the rat medial prefrontal cortex is mediated by beta-adrenoceptors. Neuropsychopharmacology 23: 162-169. (Pubitemid 30406900)
28. Paxinos GFK (2001). The mouse brain in stereotaxic coordinates 2nd edn. Academic Press: San Diego.
29. Ralph RJ, Caine SB (2005). Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. J Pharmacol Exp Ther 312: 733-741. (Pubitemid 40189573)
30. Ralph RJ, Paulus MP, Fumagalli F, Caron MG, Geyer MA (2001). Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J Neurosci 21: 305-313. (Pubitemid 32098754)
31. Schmajuk NA, Larrauri JA (2005). Neural network model of prepulse inhibition. Behav Neurosci 119: 1546-1562. (Pubitemid 43145726)
32. Schroeter S, Apparsundaram S, Wiley RG, Miner LH, Sesack SR, Blakely RD (2000). Immunolocalization of the cocaine-and antidepressant-sensitive l-norepinephrine transporter. J Comp Neurol 420: 211-232. (Pubitemid 30185979)
33. Shen HW, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, Yamamoto H et al (2004). Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 29: 1790-1799. (Pubitemid 39336790)
34. Shoemaker JM, Saint Marie RL, Bongiovanni MJ, Neary AC, Tochen LS, Swerdlow NR (2005). Prefrontal D1 and ventral hippocampal N-methyl-D-aspartate regulation of startle gating in rats. Neuroscience 135: 385-394. (Pubitemid 41317377)
35. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R et al (1998). Cocaine reward models: conditioned place preference can be established in dopamine-and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA 95: 7699-7704. (Pubitemid 28293316)
36. Stone EA, Zhang Y, John SM, Bing G (1991). c-Fos response to administration of catecholamines into brain by microdialysis. Neurosci Lett 133: 33-35.
37. Sumner BE, Cruise LA, Slattery DA, Hill DR, Shahid M, Henry B (2004). Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs. Psychopharmacology (Berl) 171: 306-321. (Pubitemid 38200069)
38. Swerdlow NR, Geyer MA, Braff DL (2001). Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 156: 194-215. (Pubitemid 32702213)
39. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL (2006). Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry 63: 1325-1335. (Pubitemid 44878517)
40. Tamminga CA (2006). The neurobiology of cognition in schizophrenia. J Clin Psychiatry 67(Suppl 9): 9-13 discussion 36-42. (Pubitemid 44369649)
41. Wan FJ, Caine SB, Swerdlow NR (1996a). The ventral subiculum modulation of prepulse inhibition is not mediated via dopamine D2 or nucleus accumbens non-NMDA glutamate receptor activity. Eur J Pharmacol 314: 9-18. (Pubitemid 26378880)
42. Wan FJ, Swerdlow NR (1996b). Sensorimotor gating in rats is regulated by different dopamine-glutamate interactions in the nucleus accumbens core and shell subregions. Brain Res 722: 168-176. (Pubitemid 26200726)
43. Wright CI, Groenewegen HJ (1995). Patterns of convergence and segregation in the medial nucleus accumbens of the rat: relationships of prefrontal cortical, midline thalamic, and basal amygdaloid afferents. J Comp Neurol 361: 383-403.
44. Yamamoto BK, Novotney S (1998). Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 71: 274-280. (Pubitemid 28292559)
45. Yamashita M, Fukushima S, Shen HW, Hall FS, Uhl GR, Numachi Y et al (2006). Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology 31: 2132-2139. (Pubitemid 44413190)
46. Zhang X, Bearer EL, Boulat B, Hall FS, Uhl GR, Jacobs RE (2010). Altered neurocircuitry in the dopamine transporter knockout mouse brain. PLoS One 5: e11506.